Monopar Therapeutics Inc (MNPR) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to Monopar Therapeutics Inc (MNPRResearch Report) yesterday and set a price target of $11.00. The company’s shares closed last Wednesday at $6.82.

According to, McCarthy is a top 100 analyst with an average return of 58.4% and a 60.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

Currently, the analyst consensus on Monopar Therapeutics Inc is a Strong Buy with an average price target of $25.50.

See today’s analyst top recommended stocks >>

Based on Monopar Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.64 million. In comparison, last year the company had a GAAP net loss of $736.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.